Pfizer’s oral antiviral drug gets clearance from FDA

Image Source: © Silviumatei |


  • Pfizer’s Paxlovid – an oral treatment to COVID-19 gets emergency use authorisation from FDA on 22 December 2021.
  • The oral drug will be provided with prescription only.
  • FDA has not approved the drug administration for more than five consecutive days.

Pfizer’s Paxlovid – an oral treatment to COVID-19 has received emergency use authorisation from Food and Drug Administration (FDA) on 22 December 2021. The drug is authorised for the treatment of adults with mild-to-moderate COVId-19 and pediatric patients that are at high risk of COVID-19.

The revolutionary pill will be available through prescription only and need to be initiated as soon as patients are diagnosed with the virus and within 5 days of symptom onset. The drug will be made available by this weekend.

Related reading: Pfizer claims it's time for a booster shot to combat against Covid; seeks FDA's nod

The approval for distribution from the Center for Disease Control is expected to come soon.

Yesterday, the company announced that it has begun with the shipping of drugs to the US already.

More about Pfizer’s Paxlovid


Paxlovid is not authorised for initiation of COVID-19 treatment; and post and pre-exposure treatment from COVID-19. Paxlovid controls the virus from replicating. Also, Paxlovid should not be considered as a substitute for vaccines.

Suggested article: How does a vaccine work? How effective is Pfizer vaccine?

How to take Paxlovid?

Paxlovid has three tables, one of ritonavir and two of nirmatrelvir. Three tables are taken together twice a day for 5 days. FDA has not approved medication for more than 5 consecutive days.

Bottom line

Considering the severe impact of COVID-19 and the need of the hour to contain the spread of the new variant, Paxlovid got approval from FDA. It is highly recommended to go through the FDA guidelines before administering.



The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media Pty Ltd (Kalkine Media, we or us), ACN 629 651 672 and is available for personal and